AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.

For instance, the price of AbbVie Inc. (NYSE:ABBV) stock is up an impressive 125% over the last five years. It's down 2.0% in the last seven days. With that in mind, it's worth seeing if the ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...